Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Lipid-derived Compounds in the Human Body01:31

Lipid-derived Compounds in the Human Body

Fats and lipids are crucial components in the human body. Some lipid-derived compounds, such as fat-soluble vitamins, eicosanoids, lipoproteins, and glycolipids, also play unique roles to support various  biological processes .
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin, delayed...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Coagulation01:09

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A novel G13-RAPGEF2-RAP1 signaling pathway critical for platelet adhesion and aggregation.

Blood·2026
Same author

Evaluation of 3 commercial assays for the measurement of tissue factor activity in human plasma.

Research and practice in thrombosis and haemostasis·2026
Same author

Tissue factor detection in mouse tissues by western blotting using commercial antibodies.

Research and practice in thrombosis and haemostasis·2026
Same author

Comparison of changes in blood cells and hemostatic biomarkers in mouse xenograft models of acute myeloid leukemia and acute promyelocytic leukemia.

Research and practice in thrombosis and haemostasis·2026
Same author

Potential Mechanisms Underlying Bleeding During Infection With Hemorrhagic Fever Viruses.

Arteriosclerosis, thrombosis, and vascular biology·2025
Same author

New light on the activators of factor XI in venous thromboembolism.

Lancet (London, England)·2025
Same journal

Inflammation as a Fulcrum in Cardiovascular Disease: The Evolving Case for High-Sensitivity C-Reactive Protein.

Trends in cardiovascular medicine·2026
Same journal

Comment on "advancing personalised care in atrial fibrillation and stroke: The potential impact of AI from prevention to rehabilitation".

Trends in cardiovascular medicine·2026
Same journal

Response to: Comment on "Advancing personalised care in atrial fibrillation and stroke: The potential impact of AI from prevention to rehabilitation" (TCM-D-26-00198).

Trends in cardiovascular medicine·2026
Same journal

High-sensitivity C-reactive protein as a prognostic biomarker in cardiovascular diseases: implications for atherosclerosis, chronic kidney disease, and heart failure - a review.

Trends in cardiovascular medicine·2026
Same journal

The cost of false dichotomies in a dynamic disease.

Trends in cardiovascular medicine·2026
Same journal

Late-presenting ST-segment elevation myocardial infarction: is it just a matter of time? From temporal cutoffs to biological staging.

Trends in cardiovascular medicine·2026
See all related articles

Related Experiment Video

Updated: May 8, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Hyperlipidemia, tissue factor, coagulation, and simvastatin.

Albert Phillip Owens1, James Robert Byrnes1, Nigel Mackman1

  • 1Department of Medicine, Division of Hematology and Oncology, McAllister Heart Institute, University of North Carolina, Chapel Hill, NC 27599, USA.

Trends in Cardiovascular Medicine
|September 11, 2013
PubMed
Summary
This summary is machine-generated.

Hyperlipidemia increases cardiovascular disease risk by promoting blood clots. Simvastatin reduces this risk by lowering tissue factor expression in monocytes, suggesting a key mechanism for statin therapy.

More Related Videos

Extracellular Vesicle Tissue Factor Activity Assay
03:53

Extracellular Vesicle Tissue Factor Activity Assay

Published on: December 29, 2023

Related Experiment Videos

Last Updated: May 8, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Extracellular Vesicle Tissue Factor Activity Assay
03:53

Extracellular Vesicle Tissue Factor Activity Assay

Published on: December 29, 2023

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Pharmacology

Background:

  • Hyperlipidemia is a major risk factor for cardiovascular disease, linked to elevated cholesterol and thrombosis.
  • Oxidized lipoproteins like oxLDL are implicated in creating a pro-thrombotic state.
  • Hematopoietic cell-derived tissue factor (TF) plays a role in coagulation and thrombosis in hyperlipidemia.

Purpose of the Study:

  • To investigate the role of hematopoietic cell-derived TF in hyperlipidemia-associated thrombosis.
  • To examine the effect of simvastatin on TF expression and coagulation in hyperlipidemia.

Main Methods:

  • Review of recent studies on TF expression in hyperlipidemia.
  • Investigation of simvastatin's impact on leukocyte TF expression, TF+ microparticles, and coagulation.

Main Results:

  • Simvastatin significantly reduced leukocyte TF expression.
  • Simvastatin decreased TF-positive microparticles and overall coagulation.
  • These findings link simvastatin's anti-coagulant effects to reduced monocyte TF expression.

Conclusions:

  • Hematopoietic cell-derived TF contributes to hyperlipidemia-associated thrombosis.
  • Simvastatin exhibits anti-coagulant activity partly by reducing monocyte TF expression.
  • This provides a mechanistic insight into statin therapy for cardiovascular disease patients.